EAM
ORIC icon

Exome Asset Management’s Oric Pharmaceuticals ORIC Stock Holding History

Exome Asset Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-120,644
Closed -$1.45M – 79
2025
Q3 		$1.45M Buy
+120,644
New +$1.27M 0.88% 42

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Exome Asset Management's ORIC Position: Q4 2025 in Review

Exome Asset Management sold out of Oric Pharmaceuticals (ORIC) in Q4 2025, closing a stake of 120,644 shares — an estimated $1.45M sold.

Exome Asset Management first reported a position in ORIC in Q3 2025 and held it in 1 quarter. The position peaked at $1.45M in Q3 2025. 164 funds tracked by Wall St. Rank hold ORIC as of Q4 2025.

  • Exome Asset Management reported no remaining Oric Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Exome Asset Management sold 120,644 Oric Pharmaceuticals shares in Q4 2025, an estimated $1.45M.
  • Exome Asset Management first reported a position in Oric Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Exome Asset Management's Oric Pharmaceuticals position peaked at $1.45M in Q3 2025.
  • 164 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q4 2025.

Based on Exome Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.